Form 4: Annexon EVP Granted Significant Equity Awards

Annexon's EVP & Chief Business Officer, Michael Overdorf, received significant equity grants including restricted stock units and stock options.

Summary

• Michael Overdorf, EVP & Chief Business Officer, was granted 62,500 Restricted Stock Units (RSUs) of Annexon, Inc. Common Stock on February 19, 2026.
• Each RSU entitles the reporting person to one share of Common Stock upon vesting, with no purchase price.
• The RSUs will vest in three annual installments, with the first 1/3rd vesting on February 19, 2027, subject to continuous service.
• Additionally, Overdorf was granted 250,000 stock options with an exercise price of $5.1 per share on February 19, 2026.
• These stock options will vest monthly over four years, with 1/48th vesting on each monthly anniversary from February 19, 2026, subject to continuous service.
• The stock options have an expiration date of February 19, 2036.
• Following these transactions, Overdorf beneficially owns 186,964 shares of Common Stock and 250,000 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies the company's commitment to retaining and incentivizing key executives, aligning their interests with long-term growth, which is generally favorable for shareholders.

Positives

• Significant equity grants to a key executive (EVP & Chief Business Officer) align management's interests with long-term shareholder value.
• The grants include 62,500 Restricted Stock Units and 250,000 stock options, indicating confidence in the company's future performance.
• The vesting schedules (annual for RSUs, monthly over four years for options) incentivize long-term retention and performance of a key executive.

Negatives

• No immediate cash investment by the executive, as these are grants rather than open market purchases.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person's continuous service with the Issuer, posing a risk of forfeiture if employment ceases.

Future Outlook

The long-term vesting schedules for both the restricted stock units and stock options suggest an expectation of continued executive service and future company performance over several years.

Industry Context

StockSavvy.ai notes that equity grants are a standard component of executive compensation packages in the biotechnology sector, particularly for companies like Annexon, Inc. (ANNX) which are often in development stages. These grants are designed to attract and retain key talent and align executive incentives with long-term shareholder value creation, a common practice across the industry.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance.
• Employees: May signal stability and commitment to executive talent, potentially boosting morale.

Next Steps

• Continued service of Michael Overdorf with Annexon, Inc. to ensure vesting of equity awards.
• Annual vesting of RSUs starting February 19, 2027.
• Monthly vesting of stock options starting February 19, 2026, over four years.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants to a key executive. While these grants align management's interests with long-term shareholder value, they do not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Annexon, ANNX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Michael Overdorf, Biotechnology